Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
Jessen, Frank ; Spottke, Annika ; Boecker, Henning ; Brosseron, Frederic ; Buerger, Katharina ; Catak, Cihan ; Fliessbach, Klaus ; Franke, Christiana et al.
Fuentes, Manuel ; Heneka, Michael T ; Janowitz, Daniel ; Kilimann, Ingo ; Laske, Christoph ; Menne, Felix ; Nestor, Peter ; Peters, Oliver ; Priller, Josef ; Pross, Verena ; Ramirez, Alfredo ; Schneider, Anja ; Speck, Oliver ; Spruth, Eike Jakob ; Teipel, Stefan ; Vukovich, Ruth ; Westerteicher, Christine ; Wiltfang, Jens ; Wolfsgruber, Steffen ; Wagner, Michael ; Düzel, Emrah
Citable Link (URL):http://resolver.sub.uni-goettingen.de/purl?gs-1/15156
Alzheimer's Research & Therapy. 2018 Feb 07;10(1):15
Abstract Background Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer’s disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decline (SCD) is a pre-mild cognitive impairment (pre-MCI) at-risk state of dementia, which emerges as a highly promising target for AD prevention. Methods The German Center for Neurodegenerative Diseases (DZNE) is conducting the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE), which focuses on the characterization of SCD in patients recruited from memory clinics. In addition, individuals with amnestic MCI, mild Alzheimer’s dementia patients, first-degree relatives of patients with Alzheimer’s dementia, and cognitively unimpaired control subjects are studied. The total number of subjects to be enrolled is 1000. Participants receive extensive clinical and neuropsychological assessments, magnetic resonance imaging, positron emission tomography, and biomaterial collection is perfomed. In this publication, we report cognitive and clinical data as well as apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) biomarker results of the first 394 baseline data sets. Results In comparison with the control group, patients with SCD showed slightly poorer performance on cognitive and functional measures (Alzheimer’s Disease Assessment Scale—cognitive part, Clinical Dementia Rating, Functional Activities Questionnaire), with all mean scores in a range which would be considered unimpaired. APOE4 genotype was enriched in the SCD group in comparison to what would be expected in the population and the frequency was significantly higher in comparison to the control group. CSF Aβ42 was lower in the SCD group in comparison to the control group at a statistical trend with age as a covariate. There were no group differences in Tau or pTau concentrations between the SCD and the control groups. The differences in all measures between the MCI group and the AD group were as expected. Conclusions The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late-stage preclinical AD. This is indicated by slightly lower performance in a range of measures in SCD in comparison to the control subjects as well as by enriched APOE4 frequency and lower CSF Aβ42 concentration. Trial registration German Clinical Trials Register DRKS00007966 . Registered 4 May 2015.